Vaxcyte Inc

Vaxcyte Inc (PCVX) News & Events

$63.620

-1.610 (-2.53%)At close

PCVX News

PCVX Events

10/7 07:00

BTIG, Jefferies, Leerink, BofA, Goldman Sachs, and Evercore ISI Act as Joint Book Running Managers for the Offering

BTIG, Jefferies, Leerink, BofA, Goldman Sachs and Evercore ISI acted as joint book running managers for the offering.

10/6 10:30

Vaxcyte Shares Drop 11.3% to $65.50

Vaxcyte is down -11.3%, or -$8.32 to $65.50.

10/5 17:00

Vaxcyte Launches $500M Public Offerings of Stock and Convertible Notes

Vaxcyte announced that it has commenced underwritten public offerings of $500M of its common stock and pre-funded warrants and $500M aggregate principal amount of convertible senior notes due 2032 in separate public offerings registered under the Securities Act of 1933, as amended. All shares of common stock, pre-funded warrants and notes to be sold in the offerings will be offered by Vaxcyte. Jefferies, Leerink Partners, BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC and Guggenheim Securities are acting as joint book-running managers for the common stock and pre-funded warrant offering. Mizuho is acting as bookrunner and BTIG is acting as lead manager for the common stock and pre-funded warrant offering. Jefferies, Leerink Partners, BofA Securities, Goldman Sachs & Co. LLC and Evercore ISI are acting as joint book-running managers for the note offering. Guggenheim Securities and Mizuho are acting as bookrunners and Needham & Company is acting as lead manager for the note offering.

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading